Meeting
2023 ASCO Genitourinary Cancers Symposium
Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).
Authors
Ronac Mamtani
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Ronac Mamtani , Hanxi Zhang , Ravi Bharat Parikh , Aaron B. Cohen , Khilna Patel , Blanca Homet Moreno , Haojie Li , Kentaro Imai , Matt D. Galsky , Rebecca A. Hubbard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 466)
DOI
10.1200/JCO.2023.41.6_suppl.466
Abstract #
466
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2022 ASCO Annual Meeting
Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center.
First Author: Jeffrey Aldrich
Poster
2020 ASCO Virtual Scientific Program
Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.
First Author: Ali Raza Khaki
Poster
2017 ASCO Annual Meeting
Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
First Author: Claud Grigg